Our Research

Discover our recent findings, catch up with news, and review in-depth resources.

Single

Publications

Single-Day Protein LC-MS Bioanalysis

This paper explains how next-generation trypsins offer faster protein digestion for LC-MS analysis with comparable performance to standard methods.
Read more

Publications

In Vitro Models for Predicting Transporter-Mediated DDIs

This paper discusses how in vitro studies can be used to predict drug-drug interactions (DDIs) caused by transporters in the body.
Read more
When One Assay Isn't Enough: Validated Immunogenicity Testing for Antibody-Drug Conjugates | Resolian Case Study

Case Studies

When One Assay Isn’t Enough: Validated Immunogenicity Testing for Antibody-Drug Conjugates

ADC immunogenicity demands more than a standard ADA assay. Resolian’s tiered, domain-specific approach delivers regulatory-ready results across the full method lifecycle.
Read more
immunogenicity graphic antibody virus 1

Case Studies

Development and Validation of an Immunogenicity Assay for Detection of Anti-AAV Antibodies

CASE STUDY – ANTI-AAV ANTIBODIES. We are experienced with a wide range of different proteins and therapeutics…
Read more
test tube shutterstock 1234763995 clear

Blog

Pharmacokinetics (PK) Urine Analysis

Whereas blood is collected for analysis at a discrete time point, urine is collected over periods of time known as collection intervals…
Read more
shutterstock 140349133 1

Case Studies

Challenges of Developing an ADA Assay for Bispecific Antibody Therapeutics and ADA Characterization

Bispecifics (Bs) are biopharmaceutical products that bind to two different targets (epitopes). These are mainly two types: IgG-like (antibodies Abs) and non-IgG-like which include Bites (bispecific T-cell engager) and DARTs (Dual-affinity Re-targeting Antibody)…
Read more
Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.